CAG
LKFT

Csenge Advisory Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Csenge Advisory Group’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-137
Closed -$14K – 682
2018
Q3 		$14K Buy
+137
New +$14.5K 0.01% 439

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Csenge Advisory Group's LKFT Position: Q4 2018 in Review

Csenge Advisory Group sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2018, closing a stake of 137 shares — an estimated $14K sold.

Csenge Advisory Group first reported a position in LKFT in Q3 2018 and held it in 1 quarter. The position peaked at $14K in Q3 2018. 85 funds tracked by Wall St. Rank hold LKFT as of Q4 2018.

  • Csenge Advisory Group reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2018 after selling out during the quarter.
  • Csenge Advisory Group sold 137 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2018, an estimated $14K.
  • Csenge Advisory Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2018 and held it in 1 quarter.
  • Csenge Advisory Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $14K in Q3 2018.
  • 85 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.